Skip to main content

Advertisement

SpringerLink
Log in

Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background and purpose

Conservative treatment represents the current therapy for early-stage breast cancer. When risk factors for local relapse exist, a tumour bed boost is required. Retrospectively, we evaluated the prognostic factors influencing local recurrence (LR), overall survival (OS) and disease-free survival (DFS).

Material and methods

After conservative treatment, 210 patients received a single-dose HDR brachytherapy (HDR-BT) boost between June 1996 and December 2005. Mean age was 57 years; 75% had invasive ductal carcinoma. The most frequent surgery was lumpectomy (55.7%); 39.4% were G3, 18.6% intraductal component >25% and only 22% had negative margins.

Results

With a mean follow-up of 85 months, at 5 and 10 years the OS was 93% and 88%, DFS 92% and 89%, and LR 3.6% and 5.3%, respectively. For LR, the risk factors were carcinoma in situ, N+ and involved margins, whereas for metastasis, the risk factors were T2 tumours, stage III, N+ and the presence of local recurrence.

Conclusions

HDR-BT boost in one fraction is an effective, simple and safe method for reducing LR. The outpatient setting and shorter treatment duration represent undeniable advantages.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialist Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trial. Lancet 366:2087–2106

    Google Scholar 

  2. Romestaing P, Lehingue Y, Carrie C et al (1997) Role of a 10 Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963–968

    PubMed  CAS  Google Scholar 

  3. Polgar C, Fodor J, Orosz Z et al (2002) Electron and high dose rate brachytherapy boost in the conservative treatment of stage I–II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol 178:615–623

    Article  PubMed  Google Scholar 

  4. Baterlink H, Horiot JC, Poortmans P et al (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10 year results of the randomized boost versus no boost EORTC 22881-10882 Trial. J Clin Oncol 25:3259–3265

    Article  Google Scholar 

  5. Holland R, Veling SH, Mravunac M et al (1985) Histologic multifocality of Tis T1 T2 breast carcinomas. Implications for clinical trials of breast conserving therapy. Cancer 56:979–990

    Article  PubMed  CAS  Google Scholar 

  6. Clemons M, Danson S, Halton T et al (2001) Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 27:67–82

    Article  PubMed  CAS  Google Scholar 

  7. Maingon P, Chapet O, Barillot I et al (2004) To boost the tumor bed: the age of reason [French]. Cancer Radiother 8:33–38

    Article  PubMed  CAS  Google Scholar 

  8. Nagykalnai T, Nemeskeri Cs, Mayer A et al (1994) Effectivity of boost radiotherapy on the local recurrence rate following breast conserving surgery plus whole breast irradiation. Proceedings of the Second European Congress on Senology, pp 591–596

  9. Clarke DH, Le MG, Sarrazin D et al (1985) Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys 11:137–145

    Article  PubMed  CAS  Google Scholar 

  10. De la Rochefordière A, Abner AL, Silver B et al (1993) Are cosmetic results following conservative surgery and radiation therapy for early breast cancer dependent on technique? Int J Radiat Oncol Biol Phys 26:601–606

    Article  Google Scholar 

  11. Mansfield CM, Kormanicky LT, Schwartz GF et al (1995) Ten years results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer 75:2328–2336

    Article  PubMed  CAS  Google Scholar 

  12. Touboul E, Belkacemi Y, Lefranc JP et al (1995) Early breast cancer: influence of type of boost (electrons vs iridium-192 implant) on local control and cosmesis after conservative surgery and radiation therapy. Radiother Oncol 34:105–113

    Article  PubMed  CAS  Google Scholar 

  13. Jacobs H (1990) Breast conserving therapy: experience with HDR afterloding iridium-192 implants. In: Martinez AA, Orton CG, Mould RF (eds) Brachytherapy HDR and LDR. Nucletron Corporation, Columbia, MD, pp 251–256

    Google Scholar 

  14. Knauerhase H, Strietzel M, Gerber B et al (2008) Tumor location, interval between surgery and radiotherapy and boost technique influence local control after breast conserving surgery and radiation: retrospective analysis of monoinstitutional long-term results. Int J Radiat Oncol Biol Phys 72:1048–1055

    Article  PubMed  Google Scholar 

  15. Nag S, Kuske RR, Vicini FA et al (2001) Brachytherapy in the treatment of breast cancer. Oncology (Williston Park) 15:195–202

    CAS  Google Scholar 

  16. Hosmer DW, Lemeshow S (2000) Applied logistic regression. University of Massachusetts, Amherst, MA

    Book  Google Scholar 

  17. Vicini F, Kini VR, Chen P (1999) Brachytherapy of the tumor bed alone after lumpectomy in selected patients with early stage breast cancer treated with breast conserving therapy. J Surg Oncol 70:30–40

    Article  Google Scholar 

  18. Hammer J, Seewald DH, Track C et al (1994) Breast cancer: primary treatment with external beam radiation therapy and high dose rate iridium implantation. Radiology 193:573–577

    PubMed  CAS  Google Scholar 

  19. Fourquet A, Campana F, Mosseri V et al (1995) Iridium 192 versus cobalt 60 boost in 3–7 cm breast cancer treated by irradiation alone: final results of a randomized trial. Radiat Oncol 34:114–120

    Article  CAS  Google Scholar 

  20. Pérez CA, Taylor ME, Halverson KJ et al (1996) Brachytherapy or electron beam boost in conservation therapy of carcinoma of the breast; a non randomized comparison. Int J Radiat Oncol Biol Phys 34:995–1007

    Article  PubMed  Google Scholar 

  21. Wazer DE, Kramer B, Schmid C et al (1997) Factors determining outcome in patients treated with interstitial implantation as a radiation boost for breast conservation therapy. Int J Radiat Oncol Biol Phys 39:381–393

    Article  PubMed  CAS  Google Scholar 

  22. Neumanova R, Petera J, Frgala T (2007) Long term outcome with interstitial brachytherapy boost in the treatment of women with early stage breast cancer. Neoplasma 54:413–423

    PubMed  CAS  Google Scholar 

  23. Hennequin C, Durdux C, Espié M et al (1999) High dose rate brachytherapy for early breast cancer: an ambulatory technique. Int J Radiat Oncol Biol Phys 45:85–90

    Article  PubMed  CAS  Google Scholar 

  24. Manning MA, Arthur DW, Schmidt-Ullrich RK et al (2000) Interstitial high-dose-rate brachytherapy boost: the feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiat Oncol Biol Phys 48:1301–1306

    Article  PubMed  CAS  Google Scholar 

  25. Beato Tortajada I, Guinot Rodríguez JL, Arribas Alpuente L et al (2005) Sobreimpresión en fracción única con braquiterapia intersticial de alta tasa en el tratamiento conservador del carcinoma de mama. Clin Transl Oncol 7:404–408

    Article  PubMed  Google Scholar 

  26. Olivotto IA, Rose MA, Osteen RT et al (1989) Late cosmetic outcome after sonservative surgery and radiotherapy: analysis of causes of cosmetic failure. Int J Radiat Oncol Biol Phys 17:747–753

    Article  PubMed  CAS  Google Scholar 

  27. Ryoo MC, Kagan AR, Wollin M et al (1989) Prognostic factors for recurrence and cosmesis in 393 patients radiation therapy for early mammary carcinoma. Radiology 17:555–559

    Google Scholar 

  28. Antonini N, Jones H, Horiot JC et al (2007) Effect of age and radiation dose on local control alter breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 82:265–271

    Article  PubMed  Google Scholar 

  29. Resch A, Potter R, Van Limbergen E et al (2002) Long term results (10 years) of intensive breast conserving therapy including a high dose and large volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol 63:47–58

    Article  PubMed  Google Scholar 

  30. Livi L, Paiar F, Saieva C et al (2007) Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiother Oncol 82:287–293

    Article  PubMed  Google Scholar 

  31. Moreno F, Guedea F, López Y et al (2000) External beam irradiation plus 192 Ir implant after breast preserving surgery in women with early breast cancer. Int J Radiat Oncol Biol Phys 48: 757–765

    Article  PubMed  CAS  Google Scholar 

  32. Ulutin HC, Ash D, Dodwell D et al (2003) Brachytherapy boost to the tumor bed in high risk patients after limited surgery for breast cancer. Clin Oncol 15:156–159

    Article  CAS  Google Scholar 

  33. Van Dongen JA, Baterlink H, Fentiman IS et al (1992) Randomized clinical trial to assess the valueof breast conserving therapy in stage I and II breast cancer: EORTC 10801 trial. Monogr Natl Cancer Inst 11:15–18

    PubMed  Google Scholar 

  34. Graham P, Fourquet A (2006) Placing the boost in breast conservation radiotherapy: a review of the role, indication and techniques for breast boost radiotherapy. Clin Oncol 18:210–219

    Article  CAS  Google Scholar 

  35. Voogd AC, Nielsen M, Petersen JL et al (2001) Differences in risk factors for local and distant recurrence of breast conserving therapy or mastectomy for stage I or II breast cancer: pooled results of two large European random trials. J Clin Oncol 19:1688–1697

    PubMed  CAS  Google Scholar 

  36. López Carrizosa MC, Samper Ots PM, Vallejo Ocaña MC, Rodríguez Pérez A (2005) Early stage breast cancer conserving therapy: high dose rate brachytherapy boost to the tumor bed. Clin Transl Oncol 7:344–350

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology Department, Hospital Central de la Defensa Gómez-Ulla, C/ Glorieta del Ejército, s/n, ES-28047, Madrid, Spain

    Aurora Rodríguez Pérez, Pilar María Samper Ots, María Concepción López Carrizosa, José Zapatero Ortuño, Juan de Dios Sáez Garrido & Manuel Joaquín Martín de Miguel

  2. Radiation Oncology Department, Hospital Doce de Octubre, Madrid, Spain

    José Fermín Pérez-Regadera Gómez

Authors
  1. Aurora Rodríguez Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pilar María Samper Ots
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María Concepción López Carrizosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José Fermín Pérez-Regadera Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José Zapatero Ortuño
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juan de Dios Sáez Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manuel Joaquín Martín de Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María Concepción López Carrizosa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodríguez Pérez, A., Samper Ots, P.M., López Carrizosa, M.C. et al. Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed. Clin Transl Oncol 14, 362–368 (2012). https://doi.org/10.1007/s12094-012-0809-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0809-z

Keywords

Search

Navigation